Celltrion Receives Approval for 20mg Yuflyma, Completing Full Dosage Lineup
Establishing a Comprehensive Dosage Lineup from Low-Weight Pediatric to Adult Patients
Enhanced Dosing Convenience with High-Concentration, Citrate-Free Formulations
Accelerating the Restructuring of the Global Adalimumab Market
Celltrion announced on March 5 that it has received product approval from the Ministry of Food and Drug Safety for the 20mg/0.2mL pre-filled syringe (PFS) formulation, a low-dose version of its autoimmune disease treatment 'Yuflyma' (ingredient: adalimumab).
With this approval, Yuflyma now offers a comprehensive high-concentration product lineup in three dosage strengths: 20mg, in addition to the existing 40mg and 80mg. In particular, the addition of the 20mg formulation enables more precise prescriptions for low-weight pediatric patients, expanding the range of options for healthcare professionals. Yuflyma is now available in all dosage ranges, from low to high, across all 12 previously approved indications, including rheumatoid arthritis, psoriasis, and pediatric Crohn's disease.
The entire Yuflyma lineup features a high-concentration formulation that eliminates citrate (citric acid salt), which can cause pain during injection, and halves the injection volume compared to lower concentrations. The company explained that its high-concentration technology minimizes the foreign body sensation felt during injection, thereby improving medication adherence among pediatric patients sensitive to pain or those who have an aversion to injections.
The original drug of Yuflyma, Humira, has seen its global sales volume shift from about KRW 12.6 trillion to KRW 6.4 trillion within just one year, accelerating the generational shift toward biosimilars. The company plans to rapidly capture the original drug’s market share following the completion of its full dosage lineup, while offering healthcare professionals a broader range of prescription choices and providing patients with optimal treatment options.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Celltrion representative stated, "With this new 20mg approval, we have established an environment for 'tailored precision treatment' optimized for each patient, from low-weight pediatric patients to adults, here in Korea. We will absorb the demand shifting from the original drug and further expand our dominance in the autoimmune disease market."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.